Good afternoon, As we continue to make significant operational progress at Kiadis, we have also been working to raise Kiadis’ profile through investor events, conference attendance and media outreach. Our CEO Arthur [...]
Regulated information - Inside information
Breda, the Netherlands / Ghent, Belgium, December 14, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline [...]
Largest fund in Europe dedicated to medical technology
Significant fundraise reflects successful investment strategy to achieve better care at lower costs
Amsterdam, 12 December 2017 – LSP, the Europe [...]
Two phase 1 studies for IMU-838 in healthy volunteers have been completed
Compound was safe and well tolerated at all doses tested
New dosing regimen was determined allowing safe administration of high [...]
Favorable tolerability profile consistent with Phase 1 data
ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study
75% of ARGX-113 treated p [...]
Workshop to be held on Monday, December 11th at 12:00 pm EST
Breda, the Netherlands / Ghent, Belgium, December 11, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone
Additional preclinical data presented on BCMA-targe [...]
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo [...]
Good afternoon, As we continue to make significant operational progress at Kiadis, we have also been working to raise Kiadis’ profile through investor events, conference attendance and media outreach. Our CEO Arthur [...]
Regulated information - Inside information
Breda, the Netherlands / Ghent, Belgium, December 14, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline [...]
Largest fund in Europe dedicated to medical technology
Significant fundraise reflects successful investment strategy to achieve better care at lower costs
Amsterdam, 12 December 2017 – LSP, the Europe [...]
Two phase 1 studies for IMU-838 in healthy volunteers have been completed
Compound was safe and well tolerated at all doses tested
New dosing regimen was determined allowing safe administration of high [...]
Favorable tolerability profile consistent with Phase 1 data
ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study
75% of ARGX-113 treated p [...]
Workshop to be held on Monday, December 11th at 12:00 pm EST
Breda, the Netherlands / Ghent, Belgium, December 11, 2017 - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]
Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone
Additional preclinical data presented on BCMA-targe [...]
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo [...]